A generic alternative indicated for Heart and Blood Pressure. This formulation supports the management of chronic physiological strain on the cardiovascular system.
Formulated to manage heart failure by addressing cardiac strain to alleviate symptoms and mitigate the risk of hospitalization and cardiovascular death in adult patients.
Mechanism of Action
Sacubitril inhibits neprilysin, increasing the levels of peptides that relax blood vessels and remove salt. Valsartan blocks the renin-angiotensin system, lowering blood pressure. Together, they strengthen the heart's ability to pump.
Route of Administration
Oral
Onset Time
Steady state in 3 days
Duration
12–24 hours
Contraindications
History of angioedema (ACE/ARB related), Concurrent use with ACE inhibitors, Diabetes using aliskiren, Severe liver impairment
Severe Adverse Events
Angioedema (life-threatening swelling), Kidney failure, Severe hyperkalemia, Severe hypotension, Fetal toxicity
Information for Entresto is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
